Abstract
Objective STXBP1-related disorders are common genetic epilepsies and neurodevelopmental disorders, but the impact of symptoms across clinical domains is poorly understood. Disease concept models are formal frameworks to assess the lived experience of individuals and their families and provide a basis for generating outcome measures.
Methods We conducted semi-structured, qualitative interviews with 19 caregivers of 16 individuals with STXBP1-related disorders and 7 healthcare professionals. We systematically coded themes using NVivo software and grouped concepts into the domains of symptoms, symptom impact and caregiver impact. We quantified the frequency of concepts throughout the life span and across clinical subgroups stratified by seizure history and developmental trajectories.
Results Over 25 hours of interviews, we coded a total of 3626 references to 38 distinct concepts. In addition to well recognized clinical features such as developmental delay (n=240 references), behavior (n=201), and seizures (n=147), we identified previously underrepresented symptoms including gastrointestinal (n=68) and respiratory symptoms (n=24) and pain (n=30). The most frequently referenced symptom impacts were autonomy (n=96), socialization (n=64), and schooling (n=61). Emotional impact (n=354), support (n=200), and daily life & activities (n=108) were highly cited caregiver impacts. We found that seizures (OR=8.84, 95% CI 5.97-13.1) were more commonly referenced in infancy than in other age groups, while behavior (OR=2.15, 95% CI 1.56-2.95), and socialization (OR=2.26, 95% CI 1.28-3.96) were more likely to be referred in childhood. We found that caregivers of individuals with ongoing seizures were less likely to reference developmental delay (OR=0.59, 95% CI 0.42-0.82), possibly due to the relatively high impact of seizures (OR=8.84, 95% CI 5.97-13.1).
Significance STXBP1-related disorders are complex conditions affecting a wide range of clinical and social domains. We comprehensively mapped symptoms and their impact on families to generate a comprehensive disease model as a foundation for clinical endpoints in future trials.
Key points
- Disease concept models (DCMs) are formal frameworks that capture the relationship between symptoms, concerns, and impact on daily life based on qualitative interviews
- Endpoints for future clinic studies involving STXBP1-related disorder need to be relevant to patients and families
- Interviewing a diverse cohort of caregivers and healthcare professionals allows DCMs to be generalizable and reveals high priority & novel disease concepts for treatment
- Disease concepts can vary depending on an affected individual’s age, necessitating longitudinal record of concepts
- Disease concepts can differ across clinical subgroups stratified by epilepsy and developmental histories making inclusion of variable disorder presentations important
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
I.H. was supported by The Hartwell Foundation through an Individual Biomedical Research Award. This work was also supported by the National Institute for Neurological Disorders and Stroke (K02 NS112600), the Eunice Kennedy Shriver National Institute of Child Health and Human Development through the Intellectual and Developmental Disabilities Research Center (IDDRC) at Childrens Hospital of Philadelphia and the University of Pennsylvania (U54 HD086984), and by intramural funds of the Childrens Hospital of Philadelphia through the Epilepsy NeuroGenetics Initiative (ENGIN). Research reported in this publication was also supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR001878. This project was also supported in part by the Institute for Translational Medicine and Therapeutics (ITMAT) Transdisciplinary Program in Translational Medicine and Therapeutics at the Perelman School of Medicine of the University of Pennsylvania. The study also received support through the EuroEPINOMICS-Rare Epilepsy Syndrome (RES) Consortium, which provided the capacity for exome sequencing, by the German Research Foundation (HE5415/3-1 to I.H.) within the EuroEPINOMICS framework of the European Science Foundation, by the German Research Foundation (DFG; HE5415/5-1, HE5415/6-1 to I.H.) by the DFG/FNR INTER Research Unit FOR2715 (We4896/4-570 1, and He5415/7-1 to I.H.), and by the Genomics Research and Innovation Network (GRIN, grinnetwork.org).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of the Childrens Hospital of Philadelphia (CHOP) Institutional Review Board (IRB 21-018734) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosures: The authors declare no conflicts of interest. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
Author Emails:
Katie R Sullivan sullivak13{at}chop.edu;
Sarah M Ruggiero ruggierosm{at}chop.edu;
Julie Xian xianj{at}chop.edu;
Kim M Thalwitzer thalwitzek{at}chop.edu
Sydni Stewart stewartsr{at}chop.edu
Mahgenn Cosico cosicom{at}chop.edu
Jackie Steinburg jackie.steinberg{at}stxbp1disorders.org
James Goss james.goss{at}stxbp1disorders.org
Anna Pfalzer annapfalzer{at}combinedbrain.org
Kyle J Horning kyle{at}combinedbrain.org
Nicole Weitzel nicole.c.weitzel{at}vanderbilt.edu
Sydney Corey sydney.a.corey{at}vanderbilt.edu
Laura Conway laura.conway{at}pennmedicine.upenn.edu
Charlene Son Rigby charlene.rigby{at}stxbp1disorders.org
Terry Jo Bichell terryjobichell{at}combinedbrain.org
Ingo Helbig helbigi{at}chop.edu;
Data Availability
The data that support the findings of this study are available on request to the corresponding author.
